Pharmacologic treatment of hyperlipidemia

American Family Physician

Volumn 84, Issue 5, 2011, Pages 551-558

  Last, Allen R ^a   Ference, Jonathan D ^b   Falleroni, Julianne ^a  

^a University's Fox Valley Family Medicine Residency Program   (United States)

^b WILKES UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; BEZAFIBRATE; BILE ACID BINDING RESIN; C REACTIVE PROTEIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; DIGOXIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NON PRESCRIPTION DRUG; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ANKLE BRACHIAL INDEX; ARTHRALGIA; ARTICLE; BLOATING; BRAIN HEMORRHAGE; BURPING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVENING DOSAGE; FLUSHING; FUNCTIONAL STATUS; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEART INFARCTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MEDICAL DECISION MAKING; MORTALITY; MYALGIA; MYOPATHY; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; QUALITY OF LIFE; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 80052497440     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. American Heart Association. Heart disease and stroke statistics-2011 update. http://circ.ahajournals.org/cgi/content/full/123/4/e18. Accessed May 27, 2011.
2. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110(6):763].
3. Grundy SM, Cleeman JI, Merz CN, et al.; Circulation. 2004;110(2):227-239.
4. National Insitute for Health and Clinical Excellence. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE clinical guideline CG67. May 8, 2008. http://www.nice.org.uk/CG67. Accessed September 13, 2010.
5. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25(10):567-579.
6. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152(2):69-77.
7. Ong HT. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM. 2005;98(8):599-614.
8. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165(7):725-730.
9. Morris S, Tiller R. Ezetimibe for hypercholesterolemia. Am Fam Physician. 2003;68(8):1595-1596.
10. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009;151(9):622-630.
11. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113-2122.
12. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875-1884.
13. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122(10):962.e1-8.
14. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
15. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001;61(2):197-206.
16. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858-868.
17. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
18. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007;100(7):1047-1051.
19. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7):498-511.
20. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.
21. Zhao YT, Chen Q, Sun YX, et al. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann Med. 2009;41(4):301-310.
22. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
23. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
24. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170(12):1032-1036.
25. Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 2010;170(12):1073-1077.
26. Green LA. Cholesterol-lowering therapy for primary prevention: still much we don't know. Arch Intern Med. 2010;170(12):1007-1008.
27. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-151.
28. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet. 1984;2(8403):600-604.
29. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-1245.
30. Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21(4):641-648.
31. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14(4):308-317.
32. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus [published correction appears in N Engl J Med. 2010;362(18):1748].
33. Ginsberg HN, Elam MB, Lovato LC, et al. N Engl J Med. 2010;362(17):1563-1574.
34. Alrasadi K, Awan Z, Alwaili K, et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atovastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). Am J Cardiol. 2008;102(10):1341-1347.
35. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314-345.
36. Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther. 2010;8(3):413-423.
37. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
38. Hooper L, Thompson RL, Harrison RA, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004;(4):CD003177.
39. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
40. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129(9):681-689.
41. Serruys PW, de Feyter P, Macaya C, et al.; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215-3222.
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
43. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006;151(2):273-281.
44. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93(8):914-921.
45. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-1903.
46. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57(2):193-200.
47. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002;360(9344):1455-1461.
48. Morantz C, Torrey B. Practice guideline briefs. Benefits of omega-3 fatty acids. Am Fam Physician. 2005;71(2):387.
49. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev. 2003;(3): CD002091.
50. Lampl Y, Lorberboym M, Gilad R, et al. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin. Clin Neuropharmacol. 2010;33(3):129-134.
51. Amarenco P, Bogousslavsky J, Callahan A III, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
52. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. 2007;(4):CD000123.
53. Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010;159(2):307-313.
54. Van Kuijk JP, Flu WJ, Witteveen OP, Voute M, Bax JJ, Poldermans D. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. J Cardiovasc Surg (Torino). 2009;50(5):599-609.
55. Grundy SM. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. BMJ. 2007;334(7601):982.
56. Kendrick M. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No. BMJ. 2007;334(7601):983.
57. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291(18):2243-2252.
58. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51(1):37-45.
59. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing. 2010;39(6):674-680.